Clinical trials - Press Releases

Date	Title	Company
06-Sep-2021	Evotec partner Bayer: Phase IIb trial shows eliapixant significantly decreases cough frequency in patients with refractory chronic cough	Evotec
31-Aug-2021	CellCarta expands its biomarker capabilities for clinical trials by adding Olink technology to its global services	CellCarta
31-Aug-2021	Kinnov-Therapeutics completes recruitment of KT-110 Phase 2 clinical trial in alcohol dependence disorders	Kinnov-Therapeutics
31-Aug-2021	New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in Delaying Disease Progression in a Broad Population of Patients with Pulmonary Arterial Hypertension (PAH)	Janssen Pharmaceutical Companies of Johnson & Johnson
31-Aug-2021	uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease	uniQure N.V.
31-Aug-2021	Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months	Sanofi
31-Aug-2021	Landmark clinical trial demonstrates empagliflozin (Jardiance®) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction (HFpEF)	Boehringer Ingelheim
27-Aug-2021	Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer.	Clinerion Ltd.
26-Aug-2021	Innovative ICR-discovered drug to enter first clinical trial, targeting HSF1 pathway	The Institute of Cancer Research, London
26-Aug-2021	Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems	Novavax
26-Aug-2021	HUTCHMED Initiates a Phase Ib/II Trial of Fruquintinib in Combination with Tislelizumab in Advanced Triple Negative Breast Cancer or Advanced Endometrial Cancer	HUTCHMED
25-Aug-2021	Almac Group and PILA PHARMA Ink Manufacturing Agreement	Almac
24-Aug-2021	LEXICON'S SOTAGLIFLOZIN DEMONSTRATES ADDITIONAL COMPELLING BENEFITS IN REDUCING CARDIOVASCULAR ENDPOINTS: RESULTS FROM SOLOIST AND SCORED TRIALS	Lexicon Pharmaceuticals, Inc.
24-Aug-2021	Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine	Bavarian Nordic A/S
24-Aug-2021	Nouscom announces first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer	Nouscom
23-Aug-2021	Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency	PTC Therapeutics, Inc.
22-Aug-2021	Anatara’s IBS-D clinical trial to leverage Microba Life Sciences’ precision microbiome analysis	Microba Life Sciences
20-Aug-2021	Almac Group and PILA PHARMA Ink Manufacturing Agreement	Almac
20-Aug-2021	Clinerion patent for technology underpinning Patient Network Explorer is published.	Clinerion Ltd.
19-Aug-2021	New England Journal of Medicine Publishes 12-Week Results from Study Evaluating Atogepant for the Preventive Treatment of Migraine	AbbVie